Cara Therapeutics (CARA) EBITDA margin US GAAP (year values)

2020 2021 2022 2023 2023   LTM ? CAGR 5 years ?
EBITDA margin, % ? 4.14% -383.0% -200.2% -579.4% -561.1%   -902.0%  
Changes by years, y/y, % +565pp -387pp +183pp -379pp +18pp     -0.5%

Cara Therapeutics. EBITDA margin, %

Cara Therapeutics. EBITDA margin, changes, pp

Cara Therapeutics (CARA) EBITDA margin US GAAP (quarter values)

2023Q4 2023Q4 2024Q1 2024Q2 2024Q3   LTM ?
EBITDA margin, % ? -1 085% -1 054% -1 343% -1 819% 0.00%   -902.0%
Changes by years, y/y, % -125pp -94pp -895pp -1 372pp +593pp    
Changes by quarters, q/q, % -493pp +32pp -289pp -476pp +1 819pp    

Cara Therapeutics. EBITDA margin, %

Cara Therapeutics. EBITDA margin, changes, pp

Cara Therapeutics. EBITDA margin, changes, pp